Protalix BioTherapeutics (PLX) EBIT Growth (1y) (2011 - 2026)
Protalix BioTherapeutics (PLX) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.55% |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | 298.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 298.63% |
| Mar 31, 2026 | 610.16% |
| Dec 31, 2025 | -164.61% |
| Sep 30, 2025 | -46.60% |
| Jun 30, 2025 | 148.29% |
| Mar 31, 2025 | 14.64% |
| Dec 31, 2024 | 228.39% |
| Sep 30, 2024 | 311.50% |
| Jun 30, 2024 | -111.88% |
| Mar 31, 2024 | -97.48% |
| Dec 31, 2023 | -125.05% |
| Sep 30, 2023 | 39.62% |
| Jun 30, 2023 | 469.68% |
| Mar 31, 2023 | -31.50% |
| Dec 31, 2022 | 56.27% |
| Sep 30, 2022 | -65.78% |
| Jun 30, 2022 | 39.73% |
| Mar 31, 2022 | 49.53% |
| Dec 31, 2021 | -300.99% |
| Sep 30, 2021 | 26.99% |